For every thalassaemia gene drug sold, a patent fee must be paid.

The payment ratio is 30%.

Bang!

Yang Haoran responded: "You are really greedy. There is no such high proportion of patent fees in the world. Are you trying to drain all our profits?"

The other party's lawyer said with a straight face: "Do I need to remind you? The pharmaceutical industry has always been known for its huge profits. It is completely different from the meager profits of other industries. The profit margin of pharmaceutical companies is generally 90%. If we charge 30%, it is already merciless.

.”

"Furthermore, medical expenses in Eagle Country are famous for being expensive. There is no price limit or centralized procurement. So the ratio is very reasonable."

"But the price of Sanqing's genetic drugs has always been relatively low."

The other party's lawyer said coldly: "That's your problem. Sanqing can be sold at a high price. I believe patients have no other choice and will still use your medicine."

"Besides, if the unit price is increased, although the sales volume will be reduced, the cost will be greatly increased and the profits will be higher. This will be better for pharmaceutical companies, isn't it? This is also in our interests."

"..." Yang Haoran was speechless this time.

He knew in his heart that the other party was right. Raising drug prices and maximizing profits was the way for most companies to survive. Although it was inconsistent with Sanqing's corporate philosophy, it was an unspoken rule in the pharmaceutical industry.

Genetic drugs, in particular, are already very costly, and they are the only ones on the market. There are no competing products, so there is no need to worry about not having enough patients, so there is no need to lower the price.

Even if it is sold at a sky-high price, there are still people paying for it. Just like the previous SMA gene drug, the unit price was as high as 2 million U.S. dollars, and it made more than a billion dollars in just two years after it was launched.

Sanqing can sell thalassemia gene drugs for more than one million US dollars. In this way, even if it pays high patent fees, its own profits will still be very considerable.

Yang Haoran sighed in his heart, alas, it's a pity that Sanqing is not a Yingguo pharmaceutical company, but a Chinese company, so naturally it can't do this.

He cheered up and began to bargain with the other party.

The two sides argued with each other until the evening, before lowering the ratio to 25%.

At this point, the other party is unwilling to continue the conversation no matter what.

In the end, the two parties reached the first round of out-of-court settlement.

Although the talks were difficult, preliminary results were achieved.

For all thalassaemia gene drugs on the market, Sanqing will pay a supplementary patent licensing fee of 25% of the profits.

Everyone walked out of the meeting room with tired faces, but there was no trace of the relaxation and joy after success in their hearts.

Everyone has a feeling that the storm is coming.
Chapter completed!